Financial Performance - Q1 2025 - Total company net sales reached $30.5 million, a 38% increase year-over-year (YoY)[10] - Tru Niagen® net sales were $21.5 million, up 24% YoY[10] - Niagen® ingredient sales increased significantly to $8.0 million, a 95% YoY increase[10] - Gross margin improved to 63.4%, a 270 basis points increase YoY[10] - Net income was $5.1 million, or $0.07 earnings per share, an increase of $5.6 million and $0.08 YoY[10] - Adjusted EBITDA was $4.9 million, up $4.2 million YoY[10] - The company ended the quarter with $55.6 million in cash and no debt, with cash provided from operations at $7.9 million year-to-date[10] Sales Mix - Q1 2025 - E-commerce accounted for 58% of net sales in Q1 2025, compared to 55% in Q1 2024[26] - Watson's & Other B2B represented 20% of net sales in Q1 2025, up from 16% in Q1 2024[26] - Food-grade Niagen® contributed 19% of net sales in Q1 2025, down from 23% in Q1 2024[26] - Tru Niagen® net sales accounted for 71% of total net sales in Q1 2025, compared to 78% in Q1 2024[27] - Niagen®-related net sales remained at 97% of total net sales in both Q1 2025 and Q1 2024[27] Financial Outlook - 2025 - The company adjusted its full-year 2025 net sales growth outlook to between 20%-25%, previously approximately 18%[10] - Adjusted general and administrative expenses outlook was revised upwards by $7.0 to $8.0 million, previously $5.0 to $6.0 million[10]

Financial Performance - Total net sales reached $30.5 million, an increase of $8.3 million or 38% year-over-year, with a gross margin of 63.4%[1][4] - Net income was $5.1 million, or $0.07 per share, compared to a net loss of $0.5 million or $(0.01) per share in the prior year quarter[7][20] - Adjusted EBITDA improved to $4.9 million, up from $0.7 million in the first quarter of 2024[7][20] - Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% year-over-year[4][5] - Cash provided by operations was $7.9 million, compared to $0.3 million in the prior year[8][20] - Net income for Q1 2025 was reported at $5,063,000, compared to a net income of $7,179,000 in Q4 2024, indicating a decrease of 29.5%[27] - Adjusted EBITDA for Q1 2025 was $4,894,000, up from $3,371,000 in Q4 2024, reflecting a growth of 45.0%[27] Future Outlook - The company expects full year 2025 net sales growth between 20% and 25%, an increase from the previous estimate of approximately 18%[4][9] Expenses and Liabilities - Selling and marketing expenses as a percentage of net sales improved by 380 basis points to 26.6%[4][10] - General and administrative expenses are expected to increase by approximately $7.0 to $8.0 million due to revised share-based compensation estimates[4][9] - Total current liabilities increased to $20,837,000 as of March 31, 2025, from $17,948,000 on December 31, 2024, an increase of 10.5%[23] Assets and Equity - Total assets increased to $81,337,000 as of March 31, 2025, up from $68,278,000 on December 31, 2024, representing a growth of 19.1%[23] - Cash and cash equivalents at the end of Q1 2025 reached $55,616,000, compared to $27,565,000 at the end of Q1 2024, marking a 101.5% increase[25] - Total stockholders' equity increased to $55,345,000 as of March 31, 2025, up from $46,094,000 on December 31, 2024, a growth of 20.0%[23] Cash Flow - Net cash provided by operating activities for Q1 2025 was $7,883,000, a significant increase from $295,000 in Q1 2024[25] - The company reported a net increase in cash and cash equivalents of $10,956,000 for Q1 2025, compared to an increase of $240,000 in Q1 2024[25] Inventory and Receivables - Trade receivables decreased to $7,052,000 as of March 31, 2025, down from $7,768,000 on December 31, 2024, a decline of 9.2%[23] - Inventories rose to $11,185,000 as of March 31, 2025, compared to $9,192,000 on December 31, 2024, an increase of 21.7%[23] Corporate Changes - The company announced a corporate name change to Niagen Bioscience, Inc. and began trading under the new Nasdaq ticker "NAGE" effective March 19, 2025[4] - The company expanded its NAD+ precursor patent portfolio with a newly granted patent covering NR salt forms[4]

Financial Performance - For the three months ended March 31, 2025, total net sales increased by approximately $8.3 million, reaching $30.5 million, a 38% increase compared to $22.2 million in the same period of 2024[107]. - Net income for the three months ended March 31, 2025, was $5.1 million, compared to a net loss of $0.5 million in the same period of 2024[107]. - Basic income per share increased to $0.07 for the three months ended March 31, 2025, compared to a loss of $0.01 per share in the prior year[107]. - Total gross profit for the three months ended March 31, 2025, was $19,331,000, a 44% increase from $13,456,000 in the same period of 2024[110]. Segment Performance - Consumer Products segment net sales grew by 24% to $21.5 million, driven by a $4.0 million increase in e-commerce sales reflecting strong consumer demand[108]. - Ingredients segment net sales doubled to $8.2 million, primarily due to $2.9 million in sales to food-grade Niagen® partners and $1.0 million from pharmaceutical-grade Niagen® launched in 2024[108]. - The consumer products segment gross profit increased by 26% to $14,094,000, while the ingredients segment saw a 125% increase to $5,068,000[110]. Operational Efficiency - Total cost of sales improved to $11.2 million, representing 37% of net sales, down from 39% in the same period of 2024, indicating enhanced operational efficiency[109]. - Sales and marketing expenses rose by $1.4 million, or 20%, to $8,117,000, but improved as a percentage of net sales by 380 basis points to approximately 27%[112]. - Research and development expenses decreased by 40% to $1,258,000, down from $2,095,000 in the prior year, reflecting normalized spending after the launch of the Niagen Plus product line[113]. - General and administrative expenses were relatively flat at $5,184,000, a 3% decrease from $5,352,000, primarily due to a reduction in credit loss expense[114]. Cash Flow and Financial Position - The company had cash and cash equivalents of approximately $55.6 million as of March 31, 2025, with $55.5 million being unrestricted[104]. - Net cash provided by operating activities was approximately $7.9 million for the three months ended March 31, 2025, compared to $0.3 million in the same period of 2024[125]. - Cash provided by financing activities was $3.1 million for the three months ended March 31, 2025, compared to a use of cash of $14,000 in the same period of 2024[128]. - The company anticipates that current cash and cash equivalents will be sufficient to meet financial obligations for at least the next twelve months[124]. Inventory and Lease Obligations - The company is obligated to purchase approximately $16.4 million of inventory under a rolling forecast with W.R. Grace between April 1, 2025, and September 30, 2025[101]. - The company amended its lease in Longmont, Colorado, resulting in an estimated increase in lease liability and right-of-use asset of approximately $1.1 million[100]. Research and Development - The company has over 300 research partnerships through its ChromaDex External Research Program (CERP™), enhancing its position in NAD+ research and development[98].

Company Overview - ChromaDex Corporation (NASDAQ: CDXC) is a bioscience company focused on cellular health and longevity, aiming to enhance the efficiency and lifespan of cells [1] Mission and Principles - Grassroots Trading emphasizes providing objective, unbiased, and balanced research, supported by solid data without emotional influences [1] - The focus is primarily on small- to mid-cap companies, offering compelling investment insights on often overlooked opportunities [1] - The scope also includes identifying potential opportunities in large- and mega-cap companies, thereby covering a broad spectrum of the dynamic equity markets [1]

ChromaDex Earnings Conference Call Fourth Quarter 2024 Nasdaq: CDXC | March 4, 2025 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward- looking statements reflect the current view about future events. Statements that are not historical in na ...

Financial Data and Key Metrics Changes - In Q4 2024, ChromaDex reported record revenues of $29.1 million, a 37% increase year-over-year, and net income of $7.2 million [9] - For the full year 2024, net revenues reached $99.6 million, reflecting a 19% growth year-over-year, with net income of $8.6 million, a significant turnaround from a net loss of $4.9 million in 2023 [9][23] - The company generated $12.1 million in positive cash flow from operations in 2024, ending the year with $44.7 million in cash and no debt [10][29] Business Line Data and Key Metrics Changes - E-commerce channel net sales were $17.3 million, a 30% increase year-over-year, while food-grade and pharmaceutical-grade Niagen ingredient sales reached $5.3 million, a 96% increase year-over-year [10][24] - Tru Niagen-related sales increased by 29%, driven by a 30% growth in e-commerce and a 26% increase in combined Watsons and other B2B sales [24] Market Data and Key Metrics Changes - The company noted a strong demand for NAD-boosting products, with a proliferation of companies entering the market, some of which engage in misleading practices [11][12] - The company is seeing increased awareness of NAD and Niagen, particularly following the launch of the Niagen IV product line [10][46] Company Strategy and Development Direction - ChromaDex plans to use its leadership position to drive consumer safety and product excellence, addressing misleading practices in the market [12][13] - The company is pursuing an investigational new drug application for the use of NR in treating ataxia telangiectasia and is working with the FDA on the NO-PARK study for Parkinson's disease [16][111] - A name change is anticipated to better align with the company's mission and strategic direction [17][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, expecting approximately 18% growth in net sales for 2025, driven by e-commerce expansion and established partnerships [31] - The management highlighted the importance of addressing fraudulent practices in the NAD market and emphasized the need for regulatory action [12][106] Other Important Information - Gross margins improved to 61.8% for the full year, reflecting operational efficiency and a favorable product mix [23][25] - General and administrative expenses are expected to increase by approximately $5 million to $6 million in 2025, primarily due to investments in business growth [33][124] Q&A Session Summary Question: Can you discuss the stick packs and their performance? - The stick packs contain 300 milligrams and have seen increased sales, with plans for a marketing campaign in 2025 [36][37] Question: What is the expectation for the second payment from Elysium? - The second payment of $1.3 million from Elysium is expected by the end of March [40][41] Question: When can we expect results from the NO PARK study? - Results are anticipated around the end of Q3 or early Q4, but the company cannot guarantee public disclosure at that time [42][44] Question: How is the food-grade Niagen segment expected to perform in 2025? - The food-grade ingredient business is expected to continue growing, with new partnerships being added [46] Question: What drove the strong e-commerce performance in Q4? - Improvements in Shopify performance, increased awareness of NAD, and publicity contributed to the strong e-commerce results [54][55] Question: What are the supply chain risks associated with Niagen IV? - While there are always risks, the company believes it has resolved previous supply chain issues and is prepared for future demand [60][65] Question: How does the company view the potential market for NR adoption? - The company sees significant potential if the ongoing Parkinson's study yields positive results, with a large addressable market [111][116] Question: Will there be a spinout for pharmaceutical initiatives? - A spinout is a possibility if capital is insufficient for drug approval, but the company does not expect this to be necessary [119][121]

Financial Data and Key Metrics Changes - In Q4 2024, the company reported record revenues of $29.1 million, a 37% increase year-over-year, and net income of $7.2 million [8][23] - For the full year 2024, net revenues reached $99.6 million, reflecting a 19% growth year-over-year, with net income of $8.6 million, a significant turnaround from a net loss of $4.9 million in 2023 [8][22] - The company generated $12.1 million in positive cash flow from operations in 2024, ending the year with $44.7 million in cash and no debt [9][28] Business Line Data and Key Metrics Changes - E-commerce channel net sales were $17.3 million, a 30% increase year-over-year, while food-grade and pharmaceutical-grade Niagen ingredient sales reached $5.3 million, a 96% increase year-over-year [9][24] - Tru Niagen-related sales increased by 29%, driven by a 30% growth in e-commerce and a 26% increase in combined Watsons and other B2B sales [23][24] Market Data and Key Metrics Changes - The company noted a growing demand for NAD-boosting products, with an increase in companies entering the market, some of which engage in misleading practices [10][11] - The company is actively working to address fraudulent activities in the market and is advocating for more regulatory oversight [11][105] Company Strategy and Development Direction - The company plans to leverage its position as an industry leader to promote consumer safety and product excellence [12] - A name change is anticipated to better align with the company's evolving mission and strategic direction [16][33] - The company is focused on expanding its pharmaceutical-grade ingredient business and enhancing its e-commerce presence [30][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the company's strong financial discipline and operational efficiency [22][32] - The company expects approximately 18% growth in net sales for 2025, driven by e-commerce expansion and established partnerships [30][32] - Management acknowledged potential risks related to supply chain issues but indicated confidence in resolving these challenges [62] Other Important Information - The company has initiated communication with the FDA regarding an investigational new drug application for NR in treating ataxia telangiectasia and is awaiting results from the NO-PARK study for Parkinson's disease [15][16] - The company plans to introduce new formulations and enhance existing products, including a subcutaneous injection version of Niagen [84] Q&A Session Summary Question: Can you discuss the stick packs and their performance? - The stick packs contain 300 milligrams and have seen increased sales, with plans for a marketing campaign in 2025 [36] Question: What is the status of the Elysium settlement? - The second payment of $1.3 million from the Elysium settlement is expected by the end of March [40] Question: When can we expect results from the NO-PARK study? - The study will be completed by June, but results may not be available until later [42] Question: How is the food-grade Niagen segment performing? - The food-grade ingredient business is expected to continue growing, with increased awareness and new partnerships [45] Question: What are the drivers behind strong e-commerce performance? - Improvements in Shopify performance and increased awareness of NAD contributed to e-commerce growth [54] Question: What is the company's strategy regarding supply chain risks? - The company has resolved previous supply chain issues and expects to maintain a steady supply moving forward [62] Question: What are the potential market opportunities for the Parkinson's study? - A positive outcome could significantly increase demand, with a large addressable market for those diagnosed with Parkinson's disease [112] Question: Will there be a spin-off for pharmaceutical initiatives? - A spin-off is a possibility if capital is insufficient for drug approval, but it is not currently expected [118]

分组1 - ChromaDex reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to break-even earnings per share a year ago, representing an earnings surprise of 50% [1] - The company achieved revenues of $29.13 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 7.47%, and showing an increase from year-ago revenues of $21.2 million [2] - ChromaDex has outperformed the S&P 500, with shares adding about 3.7% since the beginning of the year, while the S&P 500 declined by 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.04 on revenues of $28.55 million, and for the current fiscal year, it is $0.12 on revenues of $120.8 million [7] - The Medical - Biomedical and Genetics industry, to which ChromaDex belongs, is currently in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Financial Performance - Full year net sales reached $99.6 million, a 19% increase from the prior year, with a gross margin of 61.8% and net income of $8.6 million[1][5][11] - Fourth quarter net sales were $29.1 million, up 37% year-over-year, with a gross margin of 62.5% and net income of $7.2 million, a significant improvement from $0.1 million in the prior year quarter[1][5][9] - Tru Niagen® sales contributed $22.7 million to fourth quarter net sales, reflecting a 29% increase from the prior year quarter[6][7] - Adjusted EBITDA for the full year was $8.5 million, a $6.6 million improvement from the previous year, while fourth quarter adjusted EBITDA was $3.4 million, up $2.1 million year-over-year[1][10][13] - Net sales for Q4 2024 reached $29,125,000, a 37.5% increase from $21,196,000 in Q4 2023[27] - Gross profit for Q4 2024 was $18,197,000, up 40.5% from $12,937,000 in Q4 2023[27] - Operating income for Q4 2024 was $7,111,000, compared to a loss of $168,000 in Q4 2023[27] - Net income for Q4 2024 was $7,179,000, a significant increase from $114,000 in Q4 2023[27] - Adjusted EBITDA for the full year 2024 was $8,504,000, compared to $1,900,000 in 2023, reflecting a substantial improvement[33] - The company reported a basic net income per share of $0.09 for Q4 2024, compared to a loss of $0.07 per share in Q4 2023[27] Cash and Assets - The company ended the year with $44.7 million in cash and no debt, with operating cash flows of $12.1 million, compared to $7.1 million in the prior year[1][14] - Cash and cash equivalents at the end of 2024 were $44,660,000, up from $27,325,000 in 2023, marking a 63.8% increase[31] - Total current assets increased to $64,102,000 in 2024 from $49,534,000 in 2023, representing a 29.3% growth[29] - Total liabilities decreased to $17,948,000 in 2024 from $20,622,000 in 2023, a reduction of 12.9%[29] Expenses and Projections - General and administrative expenses decreased by $6.6 million year-over-year, primarily due to lower royalty expenses and credit loss recoveries[1][16] - Selling and marketing expenses are expected to increase in absolute dollars but remain stable as a percentage of net sales, reflecting strategic investments in brand awareness[1][17] - Research and development expenses for the full year 2024 were $6,016,000, an increase from $4,958,000 in 2023[27] - For 2025, the company projects approximately 18% year-over-year revenue growth, with slight improvements in gross margin and increased general and administrative expenses of $5.0 to $6.0 million[1][17] Product Development and Regulatory - In 2024, ChromaDex launched Niagen Plus, a new product line featuring pharmaceutical-grade Niagen®, now available at over 475 wellness clinics in the U.S.[1][6] - The company received Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for NR, and is advancing its Investigational New Drug application for Ataxia Telangiectasia[1][6]

Financial Performance - The company recorded a net income of approximately $8.6 million for the year ended December 31, 2024, compared to a net loss of $4.9 million for 2023, with an accumulated deficit of approximately $181.9 million as of December 31, 2024[85]. - Total assets increased to $68,278 million in 2024 from $54,964 million in 2023, representing a growth of 24.1%[266]. - Net sales for 2024 reached $99,597 million, up 19.2% from $83,570 million in 2023[268]. - Gross profit improved to $61,586 million in 2024, a 21.4% increase compared to $50,780 million in 2023[268]. - Operating income turned positive at $7,726 million in 2024, compared to an operating loss of $5,599 million in 2023[268]. - Cash and cash equivalents increased to $44,660 million at the end of 2024, up from $27,325 million at the end of 2023, marking a 63.7% increase[273]. - Total stockholders' equity rose to $46,094 million in 2024 from $28,456 million in 2023, reflecting a growth of 62.0%[266]. - The company anticipates that its current cash and cash equivalents, along with cash generated from net sales, will be sufficient to meet financial obligations for at least the next twelve months[314]. Competition and Market Risks - The company faces significant competition from larger companies with greater financial resources, which may impact its market position and ability to launch new products[94]. - The company faces intense competition in its markets, with competitors potentially developing superior technologies that could harm its business[98]. - Economic conditions, including inflation and geopolitical issues, may negatively impact the company's business, financial condition, and share price, leading to decreased demand for its products[88]. - The success of the company's consumer product business is linked to the growth rate of the wellness industry market, particularly the dietary supplement market[91]. Operational Challenges - The company relies on a single supplier for key raw materials, which poses risks to its production capabilities and overall business operations[84]. - The company relies on contract manufacturers for pharmaceutical-grade Niagen®, and any failure by these facilities could significantly impact the ability to meet consumer demand[124]. - The company may struggle to monetize its products for pharmaceutical applications due to challenges in securing partnerships and regulatory approvals[114]. - The company may need to restructure its operations in response to changing market conditions, which could increase costs and impact profitability[97]. - The company relies on key personnel for its operations, and the loss of any critical team members could adversely affect its business[113]. Regulatory and Compliance Risks - Regulatory approvals for the company's products may be difficult to obtain or maintain, potentially leading to narrower approved indications than desired[136]. - The company faces significant compliance costs and potential liabilities related to evolving data privacy and security regulations[154]. - Changes in government regulations could impact the demand for the company's products and services, as well as its ability to comply with new regulations[146]. - The company must navigate complex data transfer regulations following the UK's withdrawal from the EEA, increasing its compliance burden[150]. Research and Development - Research and development expenses increased to $6,016 million in 2024, up 21.4% from $4,958 million in 2023, indicating a focus on innovation[268]. - The company has invested substantial resources in developing new products, but commercialization may require additional investment and regulatory approval[133]. Financial Position and Capital Needs - The company may require additional financing to meet long-term capital requirements, with potential funding sources including equity or debt financings, but there are no commitments for such financing[86]. - The company may seek additional capital within the next twelve months to fund projected operating plans and longer-term strategic objectives[314]. - The company has never paid cash dividends and does not anticipate doing so in the foreseeable future, limiting returns on investment to stock price appreciation[164]. Customer and Vendor Concentration - Major customers accounted for 12.5% and 11.7% of revenues in 2024 from A.S. Watson Group and Life Extension, respectively[323]. - As of December 31, 2024, approximately 72% of the total outstanding trade receivables were concentrated among three customers, posing a potential risk to financial performance[329]. - The Company has a major vendor, Vendor A, accounting for 47.2% of total accounts payable as of December 31, 2024, down from 64.3% in 2023[331]. Stock and Equity - The company has approximately 10.4 million outstanding options at a weighted average exercise price of $3.27 per share, which could affect the market price of its common stock[165]. - The company may experience significant dilution of stockholder equity if future operations or acquisitions are financed through additional equity offerings[179]. - The company’s stock may be thinly traded, leading to challenges in selling shares at desired prices[178]. Environmental, Social, and Governance (ESG) Considerations - The company faces increased scrutiny regarding its environmental, social, and governance (ESG) practices, which may lead to additional costs and risks[172]. - New California laws, effective in 2026, will impose broad climate-related disclosure obligations on certain companies, potentially affecting operations and increasing expenses[172]. - Investor advocacy groups are increasingly focused on ESG practices, which may influence investment decisions away from the company if perceived inadequacies exist[174].